QuantRx Biomedical Corporation (OTCBB: QTXB) Closed at $0.37. Today announced that the U.S. Food and Drug Administration (FDA) has granted the Company 510(k) clearance on its RapidSense drugs-of-abuse (DOA) Methamphetamine test. The RapidSense Methamphetamine test is the first of QuantRx’ DOA tests based solely on its proprietary technology approved by the FDA. The RapidSense Methamphetamine test is a one-step positive read lateral flow device intended for use in the professional markets.
What They Do: The QuantRx strategy targets significant market opportunities estimated to be in excess of $5 billion worldwide. The Company's technology portfolio, with more than three dozen patents, patents pending and licensed patents.
How They Trade: QTXB has a 52 week high of $1.11. and a 52 week low of $0.37.
Solar Power (OTCBB: SOPW) Closed at $1.02. Today announced it has completed its first sale to a prominent German solar integrator of its photovoltaic (“PV”) solar modules for use in the integrator’s Germany-based installation projects. An initial supply of SPI’s 200-watt panels was shipped to the integrator at the end of December 2008. The transaction follows IEC certification in early December 2008 of SPI’s family of solar modules by VDE laboratories located in Main, Germany. The IEC certification, similar to a UL listing in the United States, affirms the solar modules’ quality and performance characteristics for use in Europe for commercial and residential applications.
What They Do: Solar Power, Inc. is a vertically integrated solar energy solution provider offering the North American residential, commercial and public sector building markets a complete solution through a single brand. With a state of the art manufacturing facility in Shenzhen, China, Solar Power, Inc. provides turnkey design-build solutions through its Roseville, California headquarters and a growing retail distribution network.
How They Trade: SOPW has a 52 week high of $4.44 and a 52 week low of $0.41.
DOR BioPharma (OTCBB: DORB) Closed at $0.09. Today announced that its program for the development of DOR201 (oral beclomethasone dipropionate) for the prevention of acute radiation enteritis has received "Fast Track" designation from the U.S. Food and Drug Administration (FDA).
Fast Track is a designation that the FDA reserves for a drug intended to treat a serious or life-threatening condition and one that demonstrates the potential to address an unmet medical need for the condition. Fast track designation is designed to facilitate the development and expedite the review of new drugs. For instance, should events warrant, DOR will be eligible to submit a new drug application (NDA) for DOR201 on a rolling basis, permitting the FDA to review sections of the NDA prior to receiving the complete submission. Additionally, NDAs for fast track development programs ordinarily will be eligible for priority review, which implies an abbreviated review time of six months.
What They Do: DOR BioPharma is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of hematopoietic cell transplantation. DOR expects to begin a confirmatory Phase 3 clinical trial of orBec® for the treatment of GI GVHD in 1H 2009. orBec® is also currently the subject of an NIH-supported, Phase 2, randomized, double-blind, placebo-controlled trial in the prevention of acute GVHD.
How They Trade: AMSC has a 52 week high of $47.53 and a 52 week low of $8.22.
Provision Interactive Technologies (OTCBB: PVHO) Closed at $0.10. Today announced that well-known technology and business veteran Gil Amelio has joined the company's Board of Advisors. Amelio has more than three decades of leadership experience in technology and business. He has served as the CEO and chairman of Apple Computer; the president, CEO and chairman of National Semiconductor; and the president of Rockwell Communication Systems, a unit of Rockwell International. The successful transformations of these companies resulted in increases in investor value of more than $9 billion USD. Currently, Amelio is on the Board of Directors of AT&T, Inc.
What They Do: Provision Interactive Technologies, Inc., a subsidiary of the publicly traded company Provision Holding, Inc.is the leading purveyor of intelligent interactive 3D holographic display technologies, software, and integrated solutions for both commercial and consumer focused applications. Provision's 3D holographic display systems represent a revolutionary technology that provides the projection of full color, high resolution videos into space detached from the screen, without any special glasses.
How They Trade: PVHO has a 52 week high of $2.80 and a 52 week low of $0.05.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for news on small-cap stocks since 1999. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select small-cap stocks, to register visit http://www.smallcapreview.com/subscribe.htm
